Answers are grounded in this paper and cite their sources.
Lysophospholipid (LPL) has long been recognized as a membrane phospholipid metabolite. Recently, however, the LPL has emerged as a candidate for diagnostic and pharmacological interest. LPLs include lysophosphatidic acid (LPA), alkyl glycerol phosphate (AGP), cyclic phosphatidic acid (cPA), and sphingosine-1-phosphate (S1P). These biologically active lipid mediators serve to promote a variety of responses that include cell proliferation, migration, and survival. These LPL-related responses are mediated by cell surface G-protein-coupled receptors and also intracellular receptor peroxisome proliferator-activated receptor gamma (PPAR γ ). In this paper, we focus mainly on the most recent findings regarding the biological function of nuclear receptor-mediated lysophospholipid signaling in mammalian systems, specifically as they relate to health and diseases. Also, we will briefly review the biology of PPAR γ and then provide an update of lysophospholipids PPAR γ ligands that are under investigation as a therapeutic compound and which are targets of PPAR γ relevant to diseases.
No takes yet. Share an insight, caveat, or question.
Tamotsu Tsukahara (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: